Browsing by Author Ehnholm, Christian

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 10 of 10
Issue DateTitleAuthor(s)Citation
2010Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetesBarter, Philip; Keech, Anthony (Tony); Mann, Kirsty; Simes, Robert John; Best, J; Ehnholm, Christian; Hamwood, S; Sullivan, David Richmond; Taskinen, M.; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbility of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes, Diabetologia: clinical and experimental diabetes and metabolism, vol.53, 9,pp 1846-1855
2007Abstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of FenofibrateBarter, Philip; Copt, Samuel; Keech, Anthony (Tony); Pardy, Christopher; Best, James; D'Emden, Michael C.; Drury, P; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; Kesaniemi, Y. Antero; Scott, Russell; Taskinen, M.; Tse, Dana; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreAbstract 3691: Features Of Metabolic Syndrome Identify Individuals With Type 2 Diabetes Mellitus At High Risk For Cardiovascular Events And Greater Absolute Benefits Of Fenofibrate, Circulation (Baltimore), vol.116, N/A,pp II_838-N/A
2005Apolipoprotein E activates the low-activity form of human phospholipid transfer protein.Rye, Kerry-Anne; Ehnholm, Christian; Janis, Minna T.; Jauhiainen, Matti; Lankinen, Hilkka; Metso, Jari; Olkkonen, Vesa M.; Strandin, Tomas; Central Clinical School: Heart Research InstituteApolipoprotein E activates the low-activity form of human phospholipid transfer protein., Biochemical and Biophysical Research Communications, vol.331,(1),2005,pp 333-340
2009The effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study.Fulcher, Greg; Keech, Anthony (Tony); Pardy, Christopher; Tse, D; D'Emden, Michael C.; Ehnholm, Christian; FIELD study investigators, Fenofibrate Intervention and Event Lowering in Diabetes; O'Brien, Richard; Scott, Russell; Taskinen, M.; Northern Clinical School: Medicine; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreThe effects of fenofibrate treatment on cardiovascular disease risk in 9795 people with type 2 diabetes and various components of the metabolic syndrome: the FIELD study., Diabetes Care, vol.32,(3),2009,pp 493-498
2011Estimated Glomerular Filtration Rate and Albuminuria are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) StudyDrury, Paul; Keech, Anthony (Tony); Pardy, Christopher; Ting, Ru Dee; Zannino, Diana; Ansquer, Jean-Claude; Colman, P. G.; Davis, T. M. E.; Dixon, P; Ehnholm, Christian; Fassett, Robert; Flack, Jeff; Whiting, M. J.; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreEstimated Glomerular Filtration Rate and Albuminuria are Independent Predictors of Cardiovascular Events and Death in Type 2 Diabetes Mellitus: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study, Diabetologia: clinical and experimental diabetes and metabolism, vol.54, 1, 2011,pp 32-43
2010Genetic Association and Interaction Analysis of USF1 and APOA5 on Lipid Levels and Atherosclerosis.Barter, Philip; Ehnholm, Christian; Karhunen, Pekka; Kauttu, Tuuli; Laurila, Pirkka-Pekka; Naukkarinen, Jussi; Peltonen, Leena; Perola, Markus; Ripatti, Samuli; Salomaa, Veikko; Silander, Kaisa; Central Clinical School: Heart Research InstituteGenetic Association and Interaction Analysis of USF1 and APOA5 on Lipid Levels and Atherosclerosis., Arteriosclerosis, Thrombosis, and Vascular Biology, vol.30, 2,pp 346-352
2007Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitusKeech, Anthony (Tony); Ehnholm, Christian; Hiukka, A.; Jauhiainen, Matti; Leinonen, E.; Sundvall, J.; Taskinen, M.; School of Public Health: NH&MRC Clinical Trials CentreLong-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus, Diabetologia: clinical and experimental diabetes and metabolism, vol.50,(10),2007,pp 2067-2075
2010A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trialsByth Wilson, Karen; Keech, Anthony (Tony); O'Connell, Rachel; Pardy, Christopher; Simes, Robert John; Voysey, Merryn; Best, James; Ehnholm, Christian; Glasziou, Paul; Scott, Russell; Sullivan, David; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreA novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials, P L o S One, vol.5, 1,pp e8580-1-e8580-10
2012Plasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD studyKeech, Anthony (Tony); Veillard, Anne-Sophie; Ehnholm, Christian; Herrmann, Markus; Sullivan, David; Whiting, Malcolm; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentrePlasma homocysteine and the risk of venous thromboembolism: Insights from the FIELD study, Clinical Chemistry and Laboratory Medicine, vol.50, 12, 2012,pp 2213-2219
2009Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrateBarter, Philip; Keech, Anthony (Tony); Simes, Robert John; Sullivan, David; Zannino, Diana; Ehnholm, Christian; Taskinen, M.; Whiting, Malcolm; Central Clinical School: Heart Research Institute; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials Centre; School of Public Health: NH&MRC Clinical Trials CentreRelationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with Type 2 diabetes treated with fenofibrate, Arteriosclerosis, Thrombosis, and Vascular Biology, vol.29, 6, 2009,pp 950-955